Wednesday, February 5, 2025
2/5/2025
Project Summary/Abstract This SBIR Phase II project follows up on a highly successful Phase I project, where we initiated the development of a new and innovative probiotic strain designed for the prevention of kidney stones. This novel probiotic strain has an optimized ability to biodegrade oxalic acid. About 75% of kidney stones consist of calcium oxalate (CaOx), and the root cause of CaOx stones is an excessive urinary oxalate levels. There are few tools available to prevent CaOx stones, and none address this root cause. Current kidney stone prevention approaches rely mostly on dietary modifications, an lean heavily increasing fluid intake. However, adherence rates are commonly below 50%. Avoiding oxalate-rich foods is also recommended to limit calcium oxalate stone growth, but again, adherence rates are low, and a low oxalate diet is difficult to follow. There are few tools available beyond dietary adjustments: Alkalinizing agents such as potassium citrate can reduce stone recurrence, but can be surprisingly costly and often cause GI distress. Thiazide diuretics increase urinary volume and reduce urinary supersaturation, but they come with frequent, potentially life-threatening adverse effects such as hypokalemia. In contrast, our probiotic is a safe, cost-effective, innovative and promising strategy for eliminating oxalic acid before it can be absorbed in the small intestine, with the goal being a reduction in oxalic acid levels in urine. The main impact of this project will be the development of an accessible, affordable and safe tool that does not have side effects seen with available treatment options. The proposed SBIR Phase II project is designed to overcome remaining steps that need to be completed before commercialization of our proposed innovation. Through Phase II Aims 1-4 we will complete critical activities, including scale-up, confirmation of efficacy in a rat model of kidney stones, and demonstrating safety and tolerability in order to obtain Generally Recognized As Safe (GRAS) affirmation. The severe physical pain and suffering, the serious adverse psychological distress, and the very serious adverse economic impact caused by kidney stones underscores the need to explore new and innovative prevention approaches. Anticipated rises in the prevalence of kidney stones and hyperoxaluria, along with the limitations of current treatments strongly emphasize the societal demand for a hyperoxaluria treatment that is not only accessible and affordable but also safe.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).